Target specific screening and its use for identifying target binders
View Patent ↗The invention relates to a modified phage display method for detecting and identifying target and target binders. The modified methods involve transforming host cells with two separate phages of a target or target library and a target-binder library, and selecting to eliminate the non-paired targets and binders. The invention also relates to antibodies that bind to complexes of target and target binders; nucleic acids encoding target and target binders peptides; and the use of sequence information inherent in the targets and target binders for target validation using in silico approaches. The invention further relates to diagnostics and therapeutics employing the disclosed target and target binder peptides or polynucletides and their use in small molecule drug discovery; diagnostic and therapeutic applications directed to cancers and similar disorders; and site directed assays for high throughput drug screening.
1. A method of selecting target and target binder pairs comprising:
(a) preparing a phage comprising a library of biological targets comprising polypeptides encoded by a cDNA library and a distinguishable first selection marker;
(b) obtaining a peptide target binder library selected from the group consisting of a random peptide phage target binder library and a cDNA library encoding a polypeptide, and a second selection marker, and the first selection marker is different from the second selection market;
(c) panning, where the target phage and the target binder phage are mixed in solution and targets and target binders are allowed to mate or form complexed pairs;
(d) transforming host cells with a mixture of the target phage and target binder phage libraries, wherein the mated or complexed pairs infect the host cells; and
selecting for host cells infected by phage that formed complexes of target and target binders based on the selection markers.
2. The method of claim 1 , wherein the first selection and second selection markers marker are selected from a group consisting of: tetracycline, ampicillin, and kanamycin.
3. The method of claim 1 , wherein the host cell is selected from the group consisting of: bacteria, mammalian, yeast, insect, and plant cells.
4. The method of claim 3 , wherein the host cell is Escherichia coli.
5. The method of claim 1 , wherein the library of biological targets in step (a) comprise a polypeptide of known function.
6. The method of claim 1 , wherein the library of biological targets in step (a) comprise a polypeptide of unknown function.
7. The method of claim 1 , wherein the library of target binders in step (a) comprise polypeptides encoded by a cDNA library.
8. A cell population comprising a mixture of phage according to steps (a) and (b) of claim 1 .